WASIQ ZAIDI: Open Payments
NPI 1710920715 · ARLINGTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$20,868 in 125 payments from 16 companies in 2025. Trend: 2023 $34,667 · 2024 $11,413 · 2025 $20,868
Speaker / faculty: $14,895Travel & lodging: $3,325Food & beverage: $2,648
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 34 | $14,582 |
| ABBVIE INC. | 41 | $5,263 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $226 |
| Alkermes, Inc. | 7 | $161 |
| Otsuka America Pharmaceutical, Inc. | 7 | $149 |
| Janssen Pharmaceuticals, Inc | 6 | $113 |
| E.R. Squibb & Sons, L.L.C. | 4 | $84 |
| Tris Pharma Inc | 3 | $68 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Indivior Inc. | 2 | $43 |
Products named: FANAPT, VRAYLAR, CAPLYTA, REXULTI, ARISTADA, COBENFY, INVEGA SUSTENNA, Dyanavel XR.
Industry payments across TX — which companies pay providers there.
